General Partner’s Written Report to the Annual General Meeting of Fresenius SE & Co. KGaA regarding items 10 and 11 of the agenda pursuant to sec. 186 para. 4 sent. 2 in conjunction with sec. 71 para. 1 no. 8 sent. 5 of the German Stock Corporation Act:

In the following, the General Partner reports on the reasons for authorizing it in certain cases to exclude the shareholders’ subscription rights in the event of a utilization of own shares (sec. 186 para. 4 sent. 2 in connection with sec. 71 para. 1 no. 8 sent. 5 of the German Stock Corporation Act). As of the date of convening the General Meeting, this report is available on the Company’s website, www.fresenius.com, under Investor Relations – Annual General Meetings, and is available for inspection at the offices of the Company. Additionally, it is available for inspection in the meeting room for the duration of the Annual General Meeting.

Under agenda item 10, it will be proposed to the Annual General Meeting that the General Partner shall be authorized to purchase and use own shares. Through this measure, it is intended to authorize the Company – in accordance with the predominant practice of large, publicly listed companies in Germany – to exploit the benefits associated with the instrument of own shares in the best interests of the Company and all its shareholders. Due to the capital increase from company funds as proposed under agenda item 7, the previous authorization granted by the Annual General Meeting on May 11, 2012 is to be adjusted in order to economically correspond to the authorization that would exist without such measure. In order to achieve maximum flexibility in the handling of own shares, it is intended to grant the authorization for the maximum period of five years permitted under stock corporation law, i.e. until May 15, 2019.

The acquisition of own shares can be effected by means of a purchase on the stock exchange, by means of a public tender offer to all shareholders by the Company itself, or an invitation to all shareholders to submit offers for sale. In the event of the last two acquisition scenarios, the shareholders can decide themselves how many shares and – if a price range is fixed, also – at what price they want to tender those shares to the Company. In any case, the General Partner will observe the principle of equal treatment provided for under German stock corporation law in accordance with sec. 53a of the German Stock Corporation Act when acquiring own shares. The proposed acquisition scenarios on the stock exchange, by way of a public tender offer made to all shareholders or by means of an invitation to submit offers for sale, all take account of that principle.

If, in the case of a public tender offer or in case of an invitation to submit sales offers, the total volume of shares offered or tendered exceeds the volume of shares that it is intended to repurchase, the Company will accept those shares on a pro-rata basis. However, it is possible to provide for a preferential acceptance of smaller numbers of shares of up to 100 shares per tendering shareholder in order to prevent arithmetical fractions of shares when the quotas to be acquired are determined, and to avoid small numbers of residual shares, thereby facilitating the technical execution as a whole.

In the event of an acquisition by way of a public tender offer or a public invitation to submit offers for sale, the purchase price offered or the limit values of the purchase price range per share (exclusive of incidental acquisition expenses - Erwerbsnebenkosten) must not exceed
or fall below the average trading price of shares of the Company in the Xetra trading system (or a comparable successor system) by more than 10% on the three exchange trading days preceding the date of the publication of the offer or the public invitation to submit an offer for sale. If significant deviations from the relevant price occur after the publication of a tender offer or public invitation to submit an offer for sale, it will be possible to adjust the offer or invitation to submit such an offer, with such adjustment being based on the relevant average price on the three exchange trading days prior to the publication of any such adjustment, if any. The tender offer or invitation to submit such an offer may be subject to further conditions.

The General Partner is authorized to use own shares purchased on the basis of this authorization for any purpose legally permissible and in particular for the following purposes:

The proposed authorization entitles the General Partner to partially or entirely redeem (einziehen) repurchased own shares bought back, in accordance with common practice among large German listed companies, without requirement for further resolution of the Annual General Meeting. In this respect, it shall also be possible to redeem the shares without a capital reduction pursuant to sec. 237 para. 3 no. 3 of the German Stock Corporation Act (called a simplified procedure). By redeeming the shares without capital reduction, the proportional amount of the residual shares in the share capital of the Company increases. Therefore, the Supervisory Board shall be authorized in this case to modify the Articles of Association with respect to the changing number of no-par value shares.

Exclusion of the subscription right in the event of a sale against payment in cash

Own shares may also be sold in ways other than on the stock exchange or by means of an offer made to all shareholders, against payment in cash and to the exclusion of the subscription rights. Thus, the Company will be placed in a position where it is able to react swiftly and flexibly to favorable market situations. Moreover, it will be possible to win additional domestic and foreign investors by selling shares, for example, to institutional investors. In order to take appropriate account of the concept of anti-dilution protection for the benefit of shareholders, the aforementioned utilization is, pursuant to sec. 186 para. 3 sent. 4 of the German Stock Corporation Act, subject to the condition that own shares may only be sold at a price which is not significantly lower than the relevant stock exchange price at the time when the shares are sold; in this respect, the sale price will be finally determined immediately prior to the disposal itself. Additionally, the permitted sales volume is limited in such cases to 10% of the Company’s existing respective share capital. The total share capital at the time of the resolution of the Annual General Meeting shall generally be decisive for the calculation of the 10% limit. As of the effective date of the capital increase from company funds to be resolved under item 7 of the agenda, the increased total share capital shall be decisive. If the total share capital at the time of the exercise of the authorization is lower, this amount shall be decisive. If any other authorization to issue or sell any shares of the Company or to issue any rights permitting or requiring the subscription of shares of the Company is used, excluding the right of subscription in direct or analogous application of sec. 186 para. 3 sent. 4 of the German Stock Corporation Act during the term of this authorization until its utilization, this is to be credited against the aforementioned 10% limit. The shareholders are thereby given the general opportunity to maintain their shareholding quota by way of a parallel acquisition of shares in the Company via the stock exchange at comparable conditions.
Exclusion of subscription rights in the event of a use of own shares against contributions in kind

Furthermore, it will also be possible to use own shares against contributions in kind within the scope of mergers and upon acquisition of companies and other assets, excluding the shareholders’ subscription right. In particular in the international globalized market of corporate transactions, it is not infrequent that a delivery of liquid shares is requested as a consideration. In this context, interesting opportunities can arise for using the Company’s shares as a liquid consideration. The Company continuously monitors the market with regard to potential opportunities to further strengthen the Company’s position on the market in the best interests of the Company and its shareholders by way of such acquisition opportunities. By using the Company’s own shares, such transactions can be executed flexibly and quickly, without having to consult the Annual General Meeting, which is often not possible due to time constraints. Additionally, such transactions can materially contribute to conserving the Company’s liquidity. Therefore, such opportunity of utilizing own shares lies in the overall interests of the Company and its shareholders. In determining the valuation ratios, the General Partner will additionally ensure that the interests of shareholders are reasonably safeguarded.

Exclusion of subscription rights in the event of a use of own shares in lieu of the utilization of any conditional capital

The authorization further provides that, in lieu of the utilization of conditional capital of the Company, own shares excluding the subscription right of shareholders can also be issued to employees of the Company and its affiliated companies, including members of the management of affiliated companies, and used to fulfill options or obligations to purchase shares of the Company granted or to be granted to employees of the Company or its affiliated companies as well as members of the management of affiliated companies. In this way, it is, for example, also intended to make it possible to offer the respective beneficiaries shares of the Company within the scope of stock option programs or employees benefit schemes – without having to resort to conditional capital. The issue of own shares to employees and officers of the Company, in particular in view of long-term compensation components having the purpose of securing the Company’s sustainable success, is in the best interests of the Company and its shareholders, since it materially promotes the identification of employees and officers with their company as well as the Company’s value as such. Furthermore, the use of existing own shares instead of having to draw on conditional capital can make economic sense for the Company.

The aforementioned opportunity to use own shares in order to discharge long-term, share-based compensation components, excluding the subscription right of shareholders, shall also be available for the benefit of the members of the General Partner’s Management Board. In order to take reasonable account of potential conflicts of interest resulting from the Company’s legal form as well as corporate governance in accordance with the German Stock Corporation Act, the corresponding authorization to use own shares will, however, not be addressed to the General Partner (represented by the Management Board), but to its Supervisory Board.

Own shares may further be used to fulfill bonds carrying option or/conversion rights or obligations, issued by the Company or dependent entities of the Company as defined in sec. 17 of the German Stock Corporation Act. In order to comply with the rights resulting therefrom, it may be appropriate, considering the Company’s interests, to partially or entirely use
own shares instead of shares resulting from a corresponding capital increase, which requires that the subscription right of shareholders be excluded.

Exclusion of subscription rights to eliminate fractional amounts

Fractional amounts, if any, may be excluded in an offer made to all shareholders. This is necessary in view of the technical processing of such offer, in order to avoid the issue of fractional amounts of shares. The General Partner will dispose of the shares excluded from the shareholders’ subscription right, so-called unassigned fractions, either by selling them on the stock exchange or in another manner at the best possible conditions for the Company.

The possible uses stated above are not limited to the Company’s own shares acquired on the basis of this authorizing resolution; they also include shares of the Company acquired pursuant to sec. 71 d sent. 5 of the German Stock Corporation Act. In this way, additional flexibility is also created in the best interests of the Company, also with a view to using such own shares in accordance with this authorizing resolution.

The Management Board will inform the Annual General Meeting of how this authorization was utilized.

Use of equity derivatives

Agenda item 11 further contains the proposal to authorize the Company to use equity derivatives when acquiring own shares according to the authorization proposed under agenda item 10. To this end, the General Partner shall be authorized (1) to sell options which require the Company to acquire shares of the Company upon exercise (hereinafter referred to as put options), (2) to acquire options which entitle the Company to acquire shares of the Company upon exercise (hereinafter referred to as call options), and (3) to transact forward purchases which entitle the Company to acquire shares of the Company on a specific future date. According to the authorization proposed under agenda item 11, the acquisition may also be made using any combination of put options, call options and forward purchases (hereinafter collectively referred to as “equity derivatives” or “derivatives”). In this regard, the proposed authorization sets forth the principle that any equity derivative used pursuant to such authorization may in total cover a maximum number of shares that does not exceed a proportional amount of 5% of the share capital of Fresenius SE & Co. KGaA at the time of the resolution of the Annual General Meeting on such authorization.

Usable equity derivatives and their benefits

The proposed authorization permits the use of put options, call options and forward purchases as well as any combination of such equity derivatives.

In the event of a sale of put options, the Company grants the buyer the right to sell shares of Fresenius SE & Co. KGaA to the Company at a price that has been fixed in the put option (exercise price). By way of consideration, the Company receives an option premium. If the put option is exercised, the option premium paid by the buyer of the put option reduces the total consideration paid by the Company for the acquisition of the share. The exercise of a put option is economically viable for the holder of the option if the price of the share of Fresenius SE & Co. KGaA is below the exercise price at the time of exercise, because then the holder of the option can sell the shares at the higher exercise price. From the Company’s point of view, the redemption of shares by means of entering into an option contract
provides the benefit that the exercise price is fixed upon conclusion of the option contract while there will be no outflow of liquidity until the exercise thereof. The use of put options for redeeming shares may, for example, be reasonable if the Company intends to redeem own shares when low prices prevail, but is unsure with respect to the optimum redemption time, i.e. the time at which the most favorable price for the share of Fresenius SE & Co. KGaA prevails. Under such circumstances it may be beneficial for the Company to sell put options, the exercise price of which is lower than the price of the share of Fresenius SE & Co. KGaA upon conclusion of the put option contract. The use of put options in particular offers the advantage that the redemption will take place at a lower price level in comparison with immediate redemption. If the holder of the option does not exercise the option because the share price prevailing on the exercise date exceeds the exercise price, the Company is unable to acquire own shares in this manner; the received option premium however remains with the Company.

In the event of an acquisition of a call option, the Company, against payment of an option premium, receives the right to purchase a pre-determined number of shares at a pre-determined price (exercise price) from the seller of the option, the option writer. The exercise of a call option is economically viable for the Company if the price of the share of Fresenius SE & Co. KGaA exceeds the exercise price, because then the Company can buy the shares at the lower exercise price from the option writer. In this manner the Company can protect itself against rising share prices. Additionally, the liquidity of the Company is conserved because the fixed purchase price for the shares must only be paid upon exercise of the call options.

In the event of a forward purchase, the Company, upon agreement with the forward seller, acquires the shares on a specific future date at a purchase price determined upon conclusion of the forward purchase. Conclusion of forward purchases may be reasonable for the Company if it wants to ensure a need for own shares on the purchase date at a specific price level.

**Term of the usable equity derivatives**

The longer the term of an equity derivative, the higher the likelihood that the Fresenius SE & Co. KGaA share price will diverge in an unpredictable way from the share price prevailing upon conclusion of the derivative contract. Therefore, the proposed authorization provides that the individual derivatives may each have a maximum term of 18 months. Furthermore, it provides that the terms of the individual derivatives must mature at the latest on May 15, 2019, and must be selected in such a manner that the acquisition of own shares upon exercise of the derivatives may not occur after May 15, 2019, the reason for this being that the authorization for redemption proposed under agenda item 10 also ends upon the expiry of May 15, 2019 and thereafter no shares can be redeemed on the basis of such authorization. Since the authorization proposed under agenda item 11 complements such authorization for redemption, concurrence of the two processes shall be ensured.

**Further details of the usable equity derivatives concept**

According to the proposed authorization, the Derivative contracts must be concluded with a credit institution or any other business fulfilling the requirements set forth in sec. 186 para.
5 sent. 1 of the German Stock Corporation Act (hereinafter collectively referred to as “Issuing Companies”).

The exercise/purchase price excluding the incidental acquisition costs may be higher or lower than the market price of the Fresenius SE & Co. KGaA share on the date of the conclusion of the derivative contract, provided however that, whether any paid or received option premium is taken into account or not, it must not exceed by more than 10%, and not fall below more than 20% of the market price of the share in the Xetra trading system (or any comparable successor system) as determined by the opening auction on the trading date on which the derivative contract was concluded. The possibility to fall below the market price by up to 20% is necessary to enable the Company even in a volatile market environment to use medium-term or long-term options for the purpose of redeeming own shares or to transact corresponding forward purchases, as the case may be.

The call option premium paid by the Company must not significantly exceed, and the put option premium received by the Company must not significantly fall below, the theoretical market value of the respective options as determined on the basis of recognized actuarial methods, such determination taking into account, inter alia, the agreed exercise price. This, as well as the limited volume of own shares that may be acquired using equity derivatives, corresponds to the basic principle of sec. 186 para. 3 sent. 4 of the German Stock Corporation Act which applies to the exclusion of subscription rights and which is applied analogously to any potential tender right. The same applies to the purchase price in the event of a forward purchase. By fixing the option premium and the exercise/purchase price as described, and through the requirement to serve options and forward purchases only with shares that have been acquired on the stock exchange at the market price of the share in the Xetra trading system (or any comparable successor system) prevailing at the date of the acquisition on the stock exchange, such requirement to be included in the terms and conditions of the derivatives, any economic disadvantage for the shareholders due to such acquisition of own shares is excluded. In this manner, the obligation of equal treatment of shareholders in accordance with the provisions in sec. 71 para. 1 No. 8 of the German Stock Corporation Act shall be fulfilled. The Issuing Company must further ensure in the terms and conditions of the derivatives that, upon acquiring shares on the stock market, the requirements stipulated in the proposed authorization for the Company are observed.

**Exclusion of any potential tender right**

If own shares are acquired using equity derivatives in compliance with the provisions set forth above, the right of the shareholders to conclude such derivative contracts with the Company is excluded pursuant to the proposed authorization. By being able to conclude the derivative contracts with an Issuing Company, the Company – in contrast to in the event of an offer to conclude equity transactions made to all shareholders – is enabled to conclude such derivative contracts on a short-term basis. This provides the Company with the necessary flexibility to react quickly to market situations.

In the event of an acquisition of own shares using such equity derivatives, the shareholders shall have the right to tender their shares only to the extent that the Company is obliged to take the shares under the derivative contracts. Any further tender right is excluded in the proposed authorization. Otherwise, it would not be possible to use the equity derivatives envisioned in the proposed authorization for the acquisition of own shares and thus the related benefits for the Company could not be achieved.
The provisions described above prevent the shareholders from incurring any significant economic disadvantage in the event of an acquisition of own shares using equity derivatives. Since the Company receives or pays, as the case may be, a fair market price, the shareholders not involved in the Derivative contracts in particular do not incur any significant value-related disadvantage. The position of the shareholders basically equals their position in the event of the redemption of shares on the stock market, where not every shareholder is actually able to sell shares to the Company. The provisions for the design of the equity derivatives and the requirements for the shares to be delivered ensure that this form of acquisition also observes the principle of equal treatment of the shareholders. Therefore, it is justified to exclude any right of the shareholders to conclude the above-mentioned derivative contracts with the Company.

Taking into consideration all of the circumstances stated above, the General Partner and the Supervisory Board consider the exclusion of any tender right to be objectively justified and appropriate vis-à-vis the shareholders. The General Partner will report to the Annual General Meeting on the details of any exercise of the authorization to redeem own shares using equity derivatives.

**Use of shares acquired using equity derivatives**

The provisions governing own shares acquired on the basis of the authorization proposed under agenda item 10 lit. b shall apply accordingly to the use of own shares acquired using equity derivatives.

Bad Homburg v.d.H., April 2014

**Fresenius SE & Co. KGaA**

**The General Partner**
**Fresenius Management SE**
**The Management Board**